Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 4/20 | 0.35 |
| ▸ | CCNK | O75909 | 2/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | KRAS | P01116 | 3/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25238790 | 0.83 | EHMT2 (0.48) | EHMT2ALDH1A1MAPK1POLB | |
| SCHEMBL25291355 | 0.79 | CCNK (0.39) | GFERCCNKCDK12HRH4EHMT2 | |
| SCHEMBL25251140 | 0.74 | PIK3CD (0.38) | CCNKCDK12ALDH1A1 | |
| SCHEMBL25252845 | 0.74 | GFER (0.39) | GFERCCNKCDK12 | |
| SCHEMBL25237461 | 0.73 | CHRM4 (0.38) | — | |
| SCHEMBL23089743 | 0.72 | JAK3 (0.38) | GFERHRH4POLB | |
| SCHEMBL25297742 | 0.72 | ALDH1A1 (0.40) | HRH4ALDH1A1MAPK1SMN1; SMN2TAAR1 | |
| SCHEMBL25884356 | 0.70 | KDM4E (0.36) | ALDH1A1 | |
| SCHEMBL25285366 | 0.67 | TAAR1 (0.40) | ALDH1A1MAPK1SMN1; SMN2TAAR1 | |
| SCHEMBL25739619 | 0.66 | USP30 (0.48) | EHMT2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | GFER 2658/4885CCNK 2189/4885CDK12 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.